T1	Participants 68 102	patients with Parkinson's disease.
T2	Participants 256 289	patients with Parkinson's disease
T3	Participants 323 427	10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine
T4	Participants 462 517	eight patients with L-dopa-induced peak-dose dyskinesia
